Vitamin E and all-cause mortality

Integrative Medicine

Volumn 4, Issue 1, 2005, Pages 14-17

  Neustadt, John ^a   Pizzorno, Joseph ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; COPPER; GAMMA TOCOPHEROL; LACTATE DEHYDROGENASE; ZINC;

CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COPPER DEFICIENCY; DEMOGRAPHY; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG EFFECT; DRUG INHIBITION; DRUG MEGADOSE; EDITORIAL; HUMAN; META ANALYSIS; METHODOLOGY; MORTALITY; SIDE EFFECT; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 28444484753     PISSN: 1546993X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (27)

1. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-Analysis: high-dosage Vitamin E supplementation may increase all-cause mortality. Ann Intern Med. Nov 10, 2004. [Epub ahead of print.]
2. Shekelle PG, Morton SC, Jungvig LK, et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med. 2004;19(4):380-389.
3. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med. 2004;164(14):1552-1556.
4. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361(9374):2017-2023.
5. Eysenck HJ. Meta-analysis and its problems. BMJ. 1994;309(6957):789-792.
6. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347(9004):781-786.
7. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288(19):2432- 2440.
8. The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):154-160.
9. MRC/BHF Heart protection study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet. 2002;360(9326):23-33.
10. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomized placebo-controlled trial. Lancet. 2000;356(9237):1213-1218.
11. Chylack LT, Jr, Brown NP, Bron A, et al. The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Ophthalmic Epidemiol. 2002;9(1):49-80.
12. McNeil JJ, Robman L, Tikellis G, et al. Vitamin E supplementation and cataract: randomized controlled trial. Ophthalmol. 2004;111(1):75-84.
13. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336(17):1216-1222.
14. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Ann Neurol. 1998;43(3):318-325.
15. Greenberg ER, Baron JA, Tosteson TD, et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. Polyp Prevention Study Group. N Engl J Med. 1994;331(3):141-147.
16. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS Report No. 9. Arch Ophthalmol. 2001;119(10):1439-1452.
17. Groff JL, Gropper SS. Chapter 12: Microminerals. in: Advanced Nutrition and Human Metabolism. 3rd ed. Belmont, Ca: Wadsworth; 2000:401-470.
18. Handelman GJ, Machlin LJ, Fitch K, Weiter JJ, Dratz EA. Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. J Nutr. 1985;115(6):807-813.
19. Burford-Maseon A. Editorial: Vitamin E and heart disease controversy: two major studies; one common flaw. J Orthomolecular Med. 2003;18(2):59-60.
20. Saldeen T, Li D, Mehta JL. Differential effects of [alpha]- and [gamma]-tocopherol on low-density lipoprotein oxidation, superoxide activity, platelet aggregation and arterial thrombogenesis. J Am College Cardiol. 1999;34(4):1208-1215.
21. Chen H, Li D, Saldeen T, Romeo F, Mehta JL. Mixed tocopherol preparation is superior to [alpha]-tocopherol alone against hypoxia-reoxygenation injury. Biochem Biophys Res Comm. 2002;291(2):349-353.
22. Ohrvall M, Sundlof G, Vessby B. Gamma, but not alpha, tocopherol levels in serum are reduced in coronary heart disease patients. J Intern Med. 1996;239(2):111-117.
23. Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. Gamma-tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci USA. 2000;97(21):11494-11499.
24. Liu M, Wallmon A, Olsson-Mortlock C, Wallin R, Saldeen T. Mixed tocopherols inhibit platelet aggregation in humans: potential mechanisms. Am J Clin Nutr. 2003;77(3):700-706.
25. Himmelfarb J, Kane J, Mcmonagle E, et al. Alpha and gamma tocopherol metabolism in healthy subjects and patients with end-stage renal disease. Kidney Int. 2003;64(3):978-991.
26. Groff JL, Gropper SS. Chapter 10: The Fat-Soluble Vitamins. in: Advanced Nutrition and Human Metabolism. 3rd ed. Belmont, Ca: Wadsworth; 2000:316-370.
27. Ceballos-Picot I, Witko-Sarsat V, Merad-Boudia M, et al. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Rad Biol Med. 1996;21(6):845-853.